Trial
NCT03387592
CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Collaborators
—
Condition
Neuroendocrine Carcinoma
Intervention
CPT-11
Why stopped
Efficacy endpoint not met according to first step of Briant-Day design
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-10